Pharmaron Beijing Co., Ltd. (Stock Code: 03759) released an announcement under Rule 13.10 of the Hong Kong Listing Rules at the request of Hong Kong Exchanges and Clearing Limited. The company confirmed that its newly reported manufacturing collaboration with the Chinese subsidiary of a leading global pharmaceutical company is being carried out in the ordinary and usual course of business.

After conducting reasonable enquiries, the board stated it is not aware of any information that must be disclosed to prevent a false market in its securities, nor is there any inside information requiring disclosure under Rule 13.09(2) of the Listing Rules and Part XIVA of the Securities and Futures Ordinance.

Shareholders and potential investors are advised to exercise caution when dealing in Pharmaron’s shares. The announcement was authorized by Chairman Dr. Lou Boliang and dated 12 March 2026.

As of the announcement date, the board comprises three executive directors (Dr. Lou Boliang, Mr. Lou Xiaoqiang, Ms. Zheng Bei), one employee representative director (Mr. Li Shing Chung Gilbert), two non-executive directors (Mr. Li Jiaqing, Ms. Wan Xuan) and three independent non-executive directors (Ms. Li Lihua, Prof. Tsang King Fung, Mr. Yu Jian).